Objectives In a post-hoc analysis, we aimed to validate the Lupus Low Disease Activity State
(LLDAS) definition as an endpoint in an systemic lupus erythematosus (SLE) Phase IIb …

In recent years, the study of systemic lupus erythematosus (SLE) patients has revealed a
central role for type I interferon (IFN) in disease pathogenesis. IFN induces the unabated …

Significant advances in the understanding of the molecular basis of innate immunity have
led to the identification of interferons (IFNs), particularly IFN-α, as central mediators in the …

Objective We investigated the mechanistic and pharmacological properties of anifrolumab, a
fully human, effector-null, anti-type I interferon (IFN) alpha receptor 1 (IFNAR1) monoclonal …

Background Ustekinumab is a monoclonal antibody targeting interleukin (IL)-12 and IL-23
and is approved for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's …

Objectives This phase II trial evaluated the efficacy and safety of an interleukin (IL) 6
monoclonal antibody for systemic lupus erythematosus (SLE). Methods Patients with active …

Objectives Type 1 interferon (IFN) is key to the pathogenesis of SLE, evidenced by the
expression of IFN-stimulated genes (ISGs) in most patients, but the clinical utility of serial …

Objective To evaluate the safety and tolerability of multiple intravenous (IV) doses of
sifalimumab in adults with moderate‐to‐severe systemic lupus erythematosus (SLE) …

Objectives A regulatory T cell (Treg) insufficiency due to shortage of interleukin-2 (IL-2) is
central to the pathophysiology of systemic lupus erythematosus (SLE). We performed a …

SLE is an autoimmune condition characterized by loss of tolerance to chromatin constituents
and the production of ANAs. The majority of SLE patients display spontaneous expression of …